Rein Therapeutics (RNTX) announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic ...

we can use machine learning to identify process errors before the solar cells are finished. We don't need any other ...

Rein Therapeutics, Inc. (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to ...

Cash, cash equivalents, and investments on December 31, 2024, were $12.9M, compared to $17.3M on December 31, 2023. “We’ve made significant ...

Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the ...